Replay available

Quest Diagnostics Incorporated (DGX) Q1 2026 Earnings Call

Quest Diagnostics Incorporated (NYSE: DGX) Q1 2026 earnings conference call, held 2026-04-21. Replay captured from the company's public earnings webcast.

Tue, April 21, 2026 at 8:30 AMendedReplay
Quest Diagnostics Incorporated (DGX) Q1 2026 Earnings Call

Investor webinar replay

Latest press releases

Companies on this event

Featured Presenters

Dan Hammerly

Interim Vice President of Investor Relations

Jim Davis

Chairman, Chief Executive Officer and President

Sam Samad

Chief Financial Officer

Michael Cherney

Analyst, Laring Partners

Elizabeth Anderson

Analyst, Evercore ISI

Patrick Dunley

Analyst, Citi

Anne Hines

Analyst, CEO of Securities

Jack Meehan

Analyst, Nefan

Anna Crescenti

Analyst, Barclays

Eric Caldwell

Analyst, Baird

Erin Wright

Analyst, Morgan Stanley

Kevin Caliendo

Analyst, UBS

Andrew Brackman

Analyst, William Blair

Lisa Gill

Analyst, JP Morgan

David Westenberg

Analyst, Piper Sandler

Replay transcript excerpt

Welcome to the Quest Diagnostics first quarter 2026 conference call. At the request of the company, this call is being recorded. The entire contents of this call, including the presentation and question and answer session that will follow, are the copyrighted property of Quest Diagnostics with all rights reserved. Any redistribution, retransmission, or rebroadcast of this call in any form without written consent of Quest Diagnostics is strictly prohibited. Now I'd like to turn the conference over to Dan Hammerly, interim vice president of investor relations for Quest Finastics. Please go ahead. Thank you and good morning. I'm joined by Jim Davis, our chairman, chief executive officer and president, and Sam Samad, our chief financial officer. During this call, we may make forward-looking statements and we'll discuss non-GAAP measures. We provide a reconciliation of non-GAAP measures to comparable GAAP measures in the table to our earnings press release actual results may differ materially from those projected. Risks and uncertainties that may affect Quest Diagnostics' future results include, but are not limited to, those described in our most recent annual report on Form 10-K and subsequently quarterly filed reports on Form 10-Q and current reports on Form 8-K. For this call, references to reported EPS refer to reported diluted EPS, and references to adjusted EPS refer to adjusted diluted EPS. Growth rates associated with our long-term outlook projections, including consolidated revenue growth, revenue growth from acquisitions, organic revenue growth, and adjusted earnings growth are compound annual growth rates. Now, here's Jim Davis. Thanks, Dan, and good morning, everyone. Our strong first quarter performance reflects a focused business delivering innovative soluti...

More from Quest Diagnostics Incorporated